{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:39:13Z","timestamp":1767973153798,"version":"3.49.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tralokinumab was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) and is the first selective interleukin (IL)-13 inhibitor that specifically neutralizes IL-13 with high affinity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the real-life short-term effectiveness and safety of tralokinumab treatment in patients with moderate-to-severe AD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicentre retrospective study was conducted including adult patients with moderate-to-severe AD who started tralokinumab treatment from 1 April to 30 June 2022 in 16 Spanish hospitals. Demographic and disease characteristics, severity and quality of life scales were collected at the baseline visit and at weeks 4 and 16.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-five patients were included. Twenty-seven patients (32%) were non-naive to advanced therapy (biological or Janus kinase inhibitors inhibitors). All included patients had severe disease with baseline Eczema Area and Severity Index (EASI) scores of 25.4 (SD 8.1), Dermatology Life Quality Index (DLQI) 15.8 (5.4) and peak pruritus numerical rating scale (PP-NRS) 8.1 (1.8) and 65% had an Investigator\u2019s Global Assessment (IGA) of 4. At week 16, there was improvement on all scales. The mean EASI decreased to 7.5 (SD 6.9, 70% improvement), SCORing Atopic Dermatitis improved 64% and PP-NRS, 57%. Also, 82%, 58% and 21% of the patients achieved EASI 50, 75 and 90, respectively. The percentage of EASI 75 responders was significantly higher among the naive vs. non-naive groups (67% vs. 41%). The safety profile was acceptable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients, with a long history of disease and prior multidrug failure, showed a good response to tralokinumab, confirming clinical trial results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llad153","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T18:47:01Z","timestamp":1682448421000},"page":"991-997","source":"Crossref","is-referenced-by-count":31,"title":["Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-5877","authenticated-orcid":false,"given":"Jos\u00e9-Juan","family":"Pereyra-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital Virgen del Roco University Hospital , Sevilla , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Herranz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital La Paz , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital San Cecilio, Instituto biosanitario de Granada , Ibs, Granada , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Elosua-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Puerta del Hierro , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Gal\u00e1n-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital , C\u00f3rdoba , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignasi","family":"Figueras-Nart","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital de Bellvitge , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Miquel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Arnau de Vilanova University Hospital , Valencia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"de la Cueva","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Infanta Leonor Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Serra-Baldrich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sant Pau Hospital , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Munera-Campos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Germans Trias i Pujol University Hospital , Badalona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Mel\u00e9-Ninot","sequence":"additional","affiliation":[{"name":"Department of Dermatology. Hospital Universitari Sagrat Cor , Grupo Quir\u00f3nsalud, Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Exp\u00f3sito-Serrano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Parc Taul\u00ed , Sabadell , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibiana","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Ramon y Cajal , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Serrano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Virgen Macarena , Sevilla , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier F","family":"Ortiz de Frutos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital 12 de Octubre , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 C","family":"Armario-Hita","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Puerto Real, University of C\u00e1diz , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"2023101016564625500_llad153-B1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2023101016564625500_llad153-B2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-016-0205-5","article-title":"Immunologic targets in atopic dermatitis and emerging therapies: an update","volume":"17","author":"Wang","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"2023101016564625500_llad153-B3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2023101016564625500_llad153-B4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/1346-8138.14116","article-title":"Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis","volume":"45","author":"Wei","year":"2018","journal-title":"J Dermatol"},{"key":"2023101016564625500_llad153-B5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I \u2013 systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023101016564625500_llad153-B6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J Mol Biol"},{"key":"2023101016564625500_llad153-B7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"2023101016564625500_llad153-B8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023101016564625500_llad153-B9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023101016564625500_llad153-B10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ced\/llad038","article-title":"Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice","volume":"48","author":"Schl\u00f6sser","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2023101016564625500_llad153-B11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40257-022-00702-2","article-title":"Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis","volume":"23","author":"Silverberg","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2023101016564625500_llad153-B12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","article-title":"The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis","volume":"83","author":"Simpson","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2023101016564625500_llad153-B13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.18176\/jiaci.0641","article-title":"Use of dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study","volume":"32","author":"Nettis","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2023101016564625500_llad153-B14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.18041","article-title":"Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series","volume":"181","author":"Armario-Hita","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023101016564625500_llad153-B15","first-page":"1","article-title":"Treatment of severe atopic dermatitis with upadacitinib in real clinical practice. Short-term efficacy and safety results","volume-title":"J Investig Allergy Clin Immunol","author":"Pereyra-Rodriguez","year":"2022"},{"key":"2023101016564625500_llad153-B16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023101016564625500_llad153-B17","doi-asserted-by":"crossref","first-page":"e644\u20135","DOI":"10.1111\/jdv.18753","article-title":"Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study","volume":"37","author":"Pezzolo","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023101016564625500_llad153-B18","author":"Ministry of Health of Spain"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad153\/50475550\/llad153.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/9\/991\/51992172\/llad153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/9\/991\/51992172\/llad153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T17:00:04Z","timestamp":1696957204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/9\/991\/7142626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,25]]},"published-print":{"date-parts":[[2023,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad153","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,4,25]]}}}